Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

J Charles Henry1, James H Peace2, Jeanette A Stewart3,4, William C Stewart3,41Little Rock Eye Clinic, Little Rock, AR, USA; 2Diabetic Eye Medical Clinic, Inglewood, CA, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas,TX, USA; 4Carolina Eye Institute, University of South Carolina, School of Me...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	J Charles Henry, James H Peace, Jeanette A Stewart, William C Stewart
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/1a2d03f680c54e799f5b5a381cfc71bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1a2d03f680c54e799f5b5a381cfc71bc
record_format	dspace
spelling	oai:doaj.org-article:1a2d03f680c54e799f5b5a381cfc71bc2021-12-02T04:51:06ZEfficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy1177-54671177-5483https://doaj.org/article/1a2d03f680c54e799f5b5a381cfc71bc2008-10-01T00:00:00Zhttp://www.dovepress.com/efficacy-safety-and-improved-tolerability-of-travoprost-bak-free-ophth-a2369https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483J Charles Henry1, James H Peace2, Jeanette A Stewart3,4, William C Stewart3,41Little Rock Eye Clinic, Little Rock, AR, USA; 2Diabetic Eye Medical Clinic, Inglewood, CA, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas,TX, USA; 4Carolina Eye Institute, University of South Carolina, School of Medicine, Columbia, SC, USAPurpose: To evaluate the efficacy, safety and tolerability of changing to travoprost BAK-free from prior prostaglandin therapy in patients with primary open-angle glaucoma or ocular hypertension.Design: Prospective, multi-center, historical control study.Methods: Patients treated with latanoprost or bimatoprost who needed alternative therapy due to tolerability issues were enrolled. Patients were surveyed using the Ocular Surface Disease Index (OSDI) to evaluate OSD symptoms prior to changing to travoprost BAK-free dosed once every evening. Patients were re-evaluated 3 months later.Results: In 691 patients, travoprost BAK-free demonstrated improved mean OSDI scores compared to either latanoprost or bimatoprost (p&nbsp;&lt; 0.0001). Patients having any baseline OSD symptoms (n = 235) demonstrated significant improvement after switching to travoprost BAK-free (p&nbsp;&lt; 0.0001). In 70.2% of these patients, symptoms were reduced in severity by at least 1 level. After changing medications to travoprost BAK-free, mean intraocular pressure (IOP) was significantly decreased (p &lt;&nbsp;0.0001). Overall, 72.4% preferred travoprost BAK-free (p &lt; 0.0001, travoprost BAK-free vs prior therapy). Travoprost BAK-free demonstrated less conjunctival hyperemia than either prior therapy (p &lt;&nbsp;0.0001).Conclusions: Patients previously treated with a BAK-preserved prostaglandin analog who are changed to travoprost BAK-free have clinically and statistically significant improvement in their OSD symptoms, decreased hyperemia, and equal or better IOP control.Keywords: glaucoma, prostaglandin analog, travoprost, latanoprost, bimatoprost, preservative, benzalkonium chloride, ocular surface disease J Charles HenryJames H PeaceJeanette A StewartWilliam C StewartDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 3, Pp 613-621 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 J Charles Henry James H Peace Jeanette A Stewart William C Stewart Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
description	J Charles Henry1, James H Peace2, Jeanette A Stewart3,4, William C Stewart3,41Little Rock Eye Clinic, Little Rock, AR, USA; 2Diabetic Eye Medical Clinic, Inglewood, CA, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas,TX, USA; 4Carolina Eye Institute, University of South Carolina, School of Medicine, Columbia, SC, USAPurpose: To evaluate the efficacy, safety and tolerability of changing to travoprost BAK-free from prior prostaglandin therapy in patients with primary open-angle glaucoma or ocular hypertension.Design: Prospective, multi-center, historical control study.Methods: Patients treated with latanoprost or bimatoprost who needed alternative therapy due to tolerability issues were enrolled. Patients were surveyed using the Ocular Surface Disease Index (OSDI) to evaluate OSD symptoms prior to changing to travoprost BAK-free dosed once every evening. Patients were re-evaluated 3 months later.Results: In 691 patients, travoprost BAK-free demonstrated improved mean OSDI scores compared to either latanoprost or bimatoprost (p&nbsp;&lt; 0.0001). Patients having any baseline OSD symptoms (n = 235) demonstrated significant improvement after switching to travoprost BAK-free (p&nbsp;&lt; 0.0001). In 70.2% of these patients, symptoms were reduced in severity by at least 1 level. After changing medications to travoprost BAK-free, mean intraocular pressure (IOP) was significantly decreased (p &lt;&nbsp;0.0001). Overall, 72.4% preferred travoprost BAK-free (p &lt; 0.0001, travoprost BAK-free vs prior therapy). Travoprost BAK-free demonstrated less conjunctival hyperemia than either prior therapy (p &lt;&nbsp;0.0001).Conclusions: Patients previously treated with a BAK-preserved prostaglandin analog who are changed to travoprost BAK-free have clinically and statistically significant improvement in their OSD symptoms, decreased hyperemia, and equal or better IOP control.Keywords: glaucoma, prostaglandin analog, travoprost, latanoprost, bimatoprost, preservative, benzalkonium chloride, ocular surface disease
format	article
author	J Charles Henry James H Peace Jeanette A Stewart William C Stewart
author_facet	J Charles Henry James H Peace Jeanette A Stewart William C Stewart
author_sort	J Charles Henry
title	Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
title_short	Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
title_full	Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
title_fullStr	Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
title_full_unstemmed	Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
title_sort	efficacy, safety, and improved tolerability of travoprost bak-free ophthalmic solution compared with prior prostaglandin therapy
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/1a2d03f680c54e799f5b5a381cfc71bc
work_keys_str_mv	AT jcharleshenry efficacysafetyandimprovedtolerabilityoftravoprostbakfreeophthalmicsolutioncomparedwithpriorprostaglandintherapy AT jameshpeace efficacysafetyandimprovedtolerabilityoftravoprostbakfreeophthalmicsolutioncomparedwithpriorprostaglandintherapy AT jeanetteastewart efficacysafetyandimprovedtolerabilityoftravoprostbakfreeophthalmicsolutioncomparedwithpriorprostaglandintherapy AT williamcstewart efficacysafetyandimprovedtolerabilityoftravoprostbakfreeophthalmicsolutioncomparedwithpriorprostaglandintherapy
_version_	1718400993826177024

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

Ejemplares similares